Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Methods in Molecular Biology (Clifton, N.J.)|November 1, 2018
Quantitative Method to Track Proteolytic Invasion in 3D CollagenKazumi Ebine, Christina R Chow, Hidayatullah G Munshi
Journal of Clinical Psychopharmacology|March 30, 2018
Vortioxetine Disposition in Obesity: Potential Implications for Patient SafetyDavid J Greenblatt, Jerold S Harmatz, Christina R Chow
Journal of Biochemistry|August 30, 2011
Signalling mechanisms of RhoGTPase regulation by the heterotrimeric G proteins G12 and G13Tohru Kozasa, Nicole Hajicek, Christina R Chow, et al.
Journal of Clinical Pharmacology|December 15, 2017
Minimal Physiologically Based Pharmacokinetic and Drug-Drug-Disease Interaction Model of Rivaroxaban and Verapamil in Healthy and Renally Impaired SubjectsMohamed Ismail, Vincent H Lee, Christina R Chow, et al.
Cellular Signalling|July 3, 2013
Modification of p115RhoGEF Ser(330) regulates its RhoGEF activityChristina R Chow, Nobuchika Suzuki, Takeshi Kawamura, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 18, 2025
Physiologically-based pharmacokinetic model for predicting drug-drug interactions perpetrated by posaconazole in healthy subjects with normal weight and obesity: Concomitant use and washoutChristopher D Bruno, Ahmed Elmokadem, David J Greenblatt, et al.
Journal of Clinical Psychopharmacology|June 1, 2018
Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient SafetyDavid J Greenblatt, Jerold S Harmatz, Michael J Ryan, et al.
Journal of Clinical Pharmacology|November 9, 2023
Clinical Consequences of Altered Drug Disposition in Obesity: Call for ChangeChristopher D Bruno, David J Greenblatt, Jerold S Harmatz, et al.
Journal of Clinical Pharmacology|June 6, 2022
Drug Disposition in Subjects With Obesity: The Research Work of Darrell R. AbernethyDavid J Greenblatt, Christopher D Bruno, Jerold S Harmatz, et al.
Pageof 3